Core Insights - Nexalin Technology, Inc. has appointed Dr. Robert Rothstein to its Scientific Advisory Board, enhancing its focus on addressing the global mental healthcare crisis, particularly in Alzheimer's disease and Traumatic Brain Injury (TBI) [1][3] Company Developments - Dr. Rothstein brings over 40 years of experience in emergency medicine and mental health, having held senior roles at institutions like the University of Chicago and Johns Hopkins Medicine, which positions him well to support Nexalin's neuropsychiatric therapeutic initiatives [2][4] - The expansion of the Scientific Advisory Board follows a reconstitution in May 2025, aligning with Nexalin's intensified focus on Alzheimer's disease and TBI, with plans to initiate Alzheimer's-specific trials in Q4 2025 [3][5] Strategic Focus - Nexalin's DIFS™ technology is believed to stimulate deep brain regions linked to memory and executive function, with ongoing research suggesting its potential benefits for TBI recovery, especially in military populations [3][5] - The company aims to leverage robust imaging biomarkers and MEG-guided protocols to support its clinical trials, ensuring rigorous oversight from the Scientific Advisory Board [5] Industry Context - The company is positioned at the intersection of bioelectronic medicine and unmet neuropsychiatric needs, with Dr. Rothstein expressing enthusiasm for the non-invasive nature of Nexalin's technology in treating Alzheimer's and TBI [4]

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the presentation of findings from the largest real-world evidence study to-date on End-tidal Control anesthesia delivery* software conducted at the University of Michigan. The results demonstrated the environmental and clinical benefits of End-tidal Control software and were presented at ANESTHESIOLOGY® 2025 taking place from October 10- 14, in San Antonio, Texas. End-tidal Control software supports the clinician in maintaini. ...

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (Nasdaq: NDRA) ("ENDRA†or the "Company†monitoring of metabolic dysfunction associated liver disease ("MASLD† ) and metabolic dysfunction associated steatohepatitis ("MASH†), today announced an aggregate of $4.9 million in commitments for a private placement (the "Offering†) led by leading institutional and cryptocurrency investors. The proceeds will be used to launch a di. ...

CHEYENNE, WYOMING / ACCESS Newswire / October 13, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) today announced the official launch of its Regulation D, Rule 506(c) investment offering (the "Offering"), marking an important milestone in the company's ongoing mission to enhance patient safety and health outcomes through advanced medical technologies. CS Diagnostics Corp. is a global medical technology company dedicated to innovation in healthcare safety and performance. ...

Core Insights - ONWARD Medical N.V. has reported strong execution in Q3 2025, with the ARC-EX System now available in over 50 US clinics, indicating accelerating adoption of its neurotechnology solutions [1][4] - The company will provide a comprehensive business and financial update on November 11, 2025 [1] Company Overview - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement and independence for individuals with spinal cord injuries and other movement disabilities [2] - The company has developed ARC Therapy, receiving 10 Breakthrough Device Designations from the FDA, and its ARC-EX System is cleared for commercial sale in the US and Europe [2] Commercial Performance - In Q3 2025, ONWARD Medical sold 40 ARC-EX Systems, demonstrating strong commercial traction [4] - The company has surpassed EUR 1 million in quarterly revenue for the first time [4] Regulatory Milestones - The ARC-EX System received CE Mark certification for improving hand strength and sensation after spinal cord injury [4] - The FDA approved an investigational device exemption for the ARC-IM System, allowing the initiation of the Empower BP global pivotal study [4] Scientific Contributions - The company announced the publication of two articles in Nature and Nature Medicine, highlighting advances in blood pressure regulation after spinal cord injury [4]

Key TakeawaysJefferies has lowered its price target for Paycom Software Inc. (PAYC) to $225 from $250, reflecting a revised outlook for the payroll software provider.The firm also initiated a Buy rating for TransMedics Group Inc. (TMDX), setting a price target of $145, indicating confidence in the organ transplant technology company.The Indian Rupee opened weaker at 88.75 against the US Dollar, compared to its previous close of 88.68, continuing a trend of depreciation influenced by foreign fund outflows an ...

Richard Drury/DigitalVision via Getty Images Third Quarter, 2025 The Fund (Class I Shares) underperformed the benchmark, the MSCI World ex USA Index, for the quarter, but outperformed the benchmark since inception. At the sector level, consumer discretionary and materials were the largest contributors to performance, while industrials and communication services were the largest detractors from performance. Geographically, the top three region allocations are 68.4% in Europe ex U.K., 11.5% in the U.K. a ...

This stock has averaged annual gains of nearly 24% over the past decade -- and its future is bright, too.I'm invested in several healthcare stocks, and the one that I'm most excited about is Intuitive Surgical (ISRG -3.19%). The stock is down 15.5% year to date as I write this, making it more attractively priced than it was last year.It's a major specialist in robotic surgery equipment, boasting more than 16 million procedures performed on its equipment and more than 9,900 machines installed in hospitals ar ...

Key Takeaways TEM expands its partnership with Northwestern Medicine, integrating its AI tool David into the EHR. TEM's AI assistant automates clinical summaries, note-taking, and treatment planning to aid clinicians. The collaboration aims to enhance workflows, cut administrative tasks, and improve patient outcomes. Tempus AI, Inc. (TEM) has expanded its longstanding collaboration with Northwestern Medicine, making it the first health system to integrate David, Tempus’ generative artificial intelligence (A ...

MESA, ARIZONA / ACCESS Newswire / October 10, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging leader in artificial intelligence-powered preventive health technologies, today highlighted the essential role of medical expertise, certified imaging data, and regulatory standards in developing trustworthy AI healthcare solutions. The company stated that while artificial intelligence has dramatically accelerated the pace of medical research, the foundation of any credible innovation still depen ...